Superworth

PMV Pharmaceuticals EPS PMVP

Diluted earnings per share by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
−$1.42
Latest quarter, Q2 FY26
−$0.34
Fiscal year 2025
−$1.49

PMV Pharmaceuticals' earnings per share was −$1.42 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.34.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.49n/a
FY2024−$1.13n/a
FY2023−$1.45n/a
FY2022−$1.61n/a
FY2021−$1.28n/a
FY2019n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.34n/a−$1.42
Q1 FY26−$0.34n/a−$1.49
Q4 FY25−$0.34n/a−$1.49
Q3 FY25−$0.40n/a−$1.59
Q2 FY25−$0.41n/a−$1.56
Q1 FY25−$0.34n/a−$1.17
Q4 FY24−$0.44n/a−$1.13
Q3 FY24−$0.37n/a−$1.00
Q2 FY24−$0.02n/a−$0.97
Q1 FY24−$0.30n/a−$1.33
Q4 FY23−$0.31n/a−$1.45
Q3 FY23−$0.34n/a−$1.56

Against its peers

Companies in Drug Manufacturers - General nearest PMV Pharmaceuticals' size, closest first, today.

CompanyEPS, 12 monthsGrowth
PMVPPMV Pharmaceuticals−$1.42
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
ATNMActinium Pharmaceuticals$0.36
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
Peer median$0.52

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on PMV Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.